TY - JOUR
T1 - Pediatric hypophosphatasia
T2 - avoid diagnosis missteps!
AU - Whyte, Michael
AU - McAlister, William H.
AU - Mack, Karen E.
AU - Mumm, Steven
AU - Madson, Katherine L.
N1 - Publisher Copyright:
© The Author(s)2024.
PY - 2024/6
Y1 - 2024/6
N2 - Hypophosphatasia(HPP) is the dento-osseous disorder caused by deactivating mutation(s) ofALPL, the gene that encodes the "tissue-nonspecific"isoenzyme of alkaline phosphatase (TNSALP). In HPP, 3 natural substrates of cell-surface TNSALP accumulate extracellularly; phosphoethanolamine (PEA), inorganic pyrophosphate (PPi), and pyridoxal 5′-phosphate (PLP). Hypophosphatasemiatogether with elevated plasma levels of PEA, PPi, and PLP comprise its biochemical signature. PPi can inhibit mineralization and in extracellular excess can impair bone and tooth hardening and perhaps explain weak muscle. Autosomal dominant or autosomal recessive inheritance from among more than 400 mutations ofALPLlargely accounts for HPP's broad-ranging severity, greatest among all skeletal diseases. Pediatric HPP spans life-threatening perinatal and infantile forms, childhood forms, and odonto-HPP selectively featuring premature loss of deciduous teeth.ALPLgene testing and TNSALP supplementation therapy have bolstered familiarity with HPP, but there are new considerations for diagnosis. Herein, diagnosis of a boy's mild childhood HPP was delayed by missteps involving his medical and dental history, physical examination, radiographic findings, and clinical laboratory studies. We review how pediatric HPP is now identified. Prompt diagnosis while appreciating the broad-ranging severity of HPP underlies the safe and effective management of this inborn-error-of-metabolism.
AB - Hypophosphatasia(HPP) is the dento-osseous disorder caused by deactivating mutation(s) ofALPL, the gene that encodes the "tissue-nonspecific"isoenzyme of alkaline phosphatase (TNSALP). In HPP, 3 natural substrates of cell-surface TNSALP accumulate extracellularly; phosphoethanolamine (PEA), inorganic pyrophosphate (PPi), and pyridoxal 5′-phosphate (PLP). Hypophosphatasemiatogether with elevated plasma levels of PEA, PPi, and PLP comprise its biochemical signature. PPi can inhibit mineralization and in extracellular excess can impair bone and tooth hardening and perhaps explain weak muscle. Autosomal dominant or autosomal recessive inheritance from among more than 400 mutations ofALPLlargely accounts for HPP's broad-ranging severity, greatest among all skeletal diseases. Pediatric HPP spans life-threatening perinatal and infantile forms, childhood forms, and odonto-HPP selectively featuring premature loss of deciduous teeth.ALPLgene testing and TNSALP supplementation therapy have bolstered familiarity with HPP, but there are new considerations for diagnosis. Herein, diagnosis of a boy's mild childhood HPP was delayed by missteps involving his medical and dental history, physical examination, radiographic findings, and clinical laboratory studies. We review how pediatric HPP is now identified. Prompt diagnosis while appreciating the broad-ranging severity of HPP underlies the safe and effective management of this inborn-error-of-metabolism.
KW - alkaline phosphatase
KW - ALPL
KW - Blount disease
KW - hyperphosphatemia
KW - hypophosphatasemia
KW - inorganic pyrophosphate
KW - metabolic bone disease
KW - osteomalacia
KW - osteoporosis
KW - phosphoethanolamine
KW - pyridoxal 5′-phosphate
KW - rickets
KW - tooth loss
KW - vitamin B6
UR - http://www.scopus.com/inward/record.url?scp=85199716101&partnerID=8YFLogxK
U2 - 10.1093/jbmr/zjae098
DO - 10.1093/jbmr/zjae098
M3 - Article
C2 - 38905292
AN - SCOPUS:85199716101
SN - 0884-0431
VL - 39
SP - 655
EP - 660
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
IS - 6
ER -